Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.43, $0.25 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $167.33 million versus the consensus estimate of $180.38 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.